August 08, 2005 13:02 ET
CALGARY, ALBERTA--(CCNMatthews - Aug. 8, 2005) - Resverlogix Corp. (TSX:RVX) announced today that on behalf of its wholly owned subsidiary, RVX Therapeutics, it has filed a patent application covering a unique and expanded application of its cardiovascular technology. RVX Therapeutics has discovered pharmaceutical compounds which have the potential to be used with medical devices such as drug-eluting stents.
The drug-eluting medical device market, primarily stents, represents a major market in the treatment of cardiovascular disease, the most common cause of death in the Western world. It is estimated that by 2010 the drug-eluting device market will generate revenues in excess of U.S. $8.0 billion annually.
"The expansion of our intellectual property into additional therapeutic applications for NEXVAS™ is an objective of our commercial strategy; to identify and cover therapeutic opportunities related to cardiovascular disease," stated Donald J. McCaffrey, President and CEO of Resverlogix Corp.
NEXVAS™ Technology: The primary focus for Resverlogix is the development of new technology designed to control cholesterol related diseases such as atherosclerosis (the buildup of plaque in the arteries). Existing drugs control the level of LDL ("bad cholesterol") in the body and thus slow atherosclerosis. Resverlogix's NEXVAS™ program is developing proprietary technology that stimulates the body to produce ApoA1 protein, the primary component of HDL, which results in increased levels of HDL ("good cholesterol"). ApoA1/HDL has been proven to not just arrest but reverse atherosclerosis by reducing existing cholesterol deposits. Activating the body to enhance ApoA1 levels is the simplest physiological or natural approach to regulating HDL.
Cardiovascular disease is the leading cause of death in industrialized countries. The drugs that are currently used to control cholesterol can only slow the progress of atherosclerosis, and yet they are the biggest selling drugs in the world with a combined market of some U.S. $30 billion annually. Resverlogix's ApoA1 technology has the potential to capture and expand much of this market.
For a more detailed explanation about NEXVAS™ technology, please access the animation on the company website at http://resverlogix.com/nexvas-apoa1.htm
About Resverlogix (RVX:TSX): Resverlogix's focus is the development of NEXVASTM technology for cardiovascular disease. In addition, the Corporation's second technology program TGF-Beta Shield™ utilizes an immunomodulating approach to target cancers and fibrotic diseases.
Resverlogix's business model is to develop proprietary technology and sell or license it to a major pharmaceutical or life science organization at an early stage of testing. In accordance with the business model Resverlogix is currently in discussion with several major pharmaceutical companies regarding the sale or licensing of its NEXVAS™ technology.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
The TSX does not accept responsibility for the adequacy or accuracy of this news release.
Resverlogix Corp.Donald J. McCaffreyPresident/CEO(403) 254-9252 ext. 223(403) 256-8495 (FAX)orResverlogix Corp.Kenneth E. LebiodaVP Business & Market Development(403) 254-9252 ext. 227(403) 256-8495 (FAX)Website: www.resverlogix.com
See all RSS Newsfeeds